Bright Peak Presents New Therapeutics Highlighted by Multifunctional PD-1 Targeted Immunocytokines at SITC 2022
– BPT567, a first-in-class PD1-IL18 immunocytokine, delivers coordinated PD-1 blockade and potent IL-18 signaling to PD-1+ T effector cells resulting in striking antitumor activity –